vTv Therapeutics Inc. ROE

ROE of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2019 was 27.17% (a 267.16% increase from previous year)
  • Annual ROE for 2018 was 7.4% (a -44.53% decrease from previous year)
  • Annual ROE for 2017 was 13.34% (a -31.1% decrease from previous year)
  • Twelve month ROE ending September 29, 2020 was 29.76% (a 3.08% increase compared to previous quarter)
  • Twelve month trailing ROE increased by 9.53% year-over-year
Trailing ROE for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
29.76% 28.87% 28.03% 27.17%
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of vTv Therapeutics Inc.

Most recent ROEof VTVT including historical data for past 10 years.

Interactive Chart of ROE of vTv Therapeutics Inc.

vTv Therapeutics Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 27.17%
2018 7.4%
2017 13.34%
2016 19.36%
2015 9.54%
2014 9.0%
2013 0.0%

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.